Today reveals real-world data from the XANTUS study presented at ESC Congress.

The findings confirm clinical trial data and demonstrate that oral anticoagulation with rivaroxaban, a direct Aspect Xa inhibitor, is safe and effective for stroke avoidance in sufferers with AF at both high – and low-risk of thromboembolic events. ‘With 10 million people in Europe alone suffering from AF, a number that is only expected to increase, real-world insights on routine anticoagulation administration in everyday medical practice is increasingly important for patients and doctors with AF,’ stated XANTUS principal investigator Professor A.The CyberKnife M6 Series delivers radiosurgery and stereotactic body radiation therapy , enabling precise, high-quality dose distributions to be shipped confidently to the individual with extreme precision over the very least number of treatments, reducing side effects and preserving patients' quality of life. The machine makes up about patient and tumor motion by adjusting automatically in real-time, ensuring on-focus on delivery of radiation.